The Children's Hospital of Philadelphia

What The Children's Hospital of Philadelphia does

The Children's Hospital of Philadelphia (CHOP) is a 501(c)(3) nonprofit pediatric health system founded in 1855 as the nation's first pediatric hospital, headquartered at 3401 Civic Center Boulevard, Philadelphia, Pennsylvania, with 10,000+ employees and 50+ locations across Pennsylvania, New Jersey, and Delaware. The institution operates two main hospital campuses (Philadelphia and King of Prussia), 30+ primary care sites, 15+ specialty and surgery centers, and community hospital affiliations including a strategic pediatric affiliation with ChristianaCare in Delaware launched April 2026. CHOP's Global Patient Services program serves international families across nearly every pediatric specialty. The hospital is consistently ranked on the U.S. News & World Report Best Children's Hospitals Honor Roll and Newsweek's World's Best Specialized Hospitals, and holds Magnet Recognition for nursing excellence.

CHOP's core technology stack combines clinical care with translational research and gene therapy development. Notable proprietary platforms include the world's first personalized CRISPR gene editing therapy (delivered via lipid nanoparticles and base editing, validated in patient KJ for CPS1 deficiency), the VLP-Open HLA nanoparticle immunotherapy platform, the RareDAI fine-tuned LLM tool for rare disease test selection (up to 20% accuracy improvement), the RADIANT multi-institutional data sharing platform spanning 35+ hospitals, the MEND decellularized cartilage technique, and ultra-rapid nanopore sequencing achieving methylation-based cancer classification in minutes. The institution runs 65+ clinical trials in cell and gene therapy and operates specialized centers including the Cancer Center, Cardiac Center, Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment (2,500+ fetal surgeries since 1995), Roberts Individualized Medical Genetics Center, and the Lurie Autism Institute. Research IP is commercialized through wholly-owned spinouts including Spark Therapeutics (Luxturna, the first FDA-approved gene therapy for inherited blindness), Latus Bio ($97M Series A in May 2026), and StrongHolt Therapeutics.

CHOP's business model blends patient care revenue, research grants, philanthropic giving, and equity participation in biotech spinouts. Patient care revenue is generated through insurance reimbursements (including Medicaid/CHIP), government programs, and patient payments across inpatient, outpatient, emergency, diagnostic, and surgical services. Research and capital funding flows from government agencies (NIH, NCI, ARPA-H), major foundations (Gates, Gilbert Family, Wyss, Pew), individual donors (e.g., $30M from Jared Isaacman in January 2026), and corporate partners. The April 2026 Labcorp strategic collaboration creates a national commercialization channel for CHOP-developed pediatric diagnostics, and the Abu Dhabi MoU opens an international training and licensing revenue stream. For FY2026 first half, CHOP reported $2.7 billion in revenue with a 6.2% operating margin, retaining position as the region's most profitable health system. Customer segments are broad and fragmented: children needing primary care, children with rare/complex conditions, emergency cases, referring physicians, and international patients.

Name

The Children's Hospital of Philadelphia

Legal name

The Children's Hospital of Philadelphia

Website

https://chop.edu

Company type

Private

Founded year

1855

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

The Children's Hospital of Philadelphia (CHOP) is a nonprofit pediatric health system founded in 1855, operating 50+ locations across Pennsylvania, New Jersey, and Delaware, with 10,000+ employees delivering primary, specialty, and emergency pediatric care alongside gene therapy research, AI-driven diagnostics, and biotech commercialization through spinouts.

Ownership category

akta.pro rank

Product category

Pediatric Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), General Medical and Surgical Hospitals (62211), Specialty (except Psychiatric and Substance Abuse) Hospitals (6223)

SIC

Services-Hospitals (8060), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Children’s Hospitals & Pediatric Health Systems (HLAFAJAG)

akta.pro secondary industries

Children’s Hospitals (Acute Care) (HLAFAAAI), Pediatrics & Adolescent Medicine Practices (HLAFAJAF), Pediatric Rehabilitation & Developmental Therapy Centers (PT/OT/SLP) (HLAFAJAL), Pediatric Urgent Care Centers (HLAFADAF), Pediatric Hematology & Oncology (HLAKAFAE)

Keywords

• Pediatric healthcare services
• Children's hospital care
• Pediatric specialty services
• Pediatric clinical research
• Gene therapy development

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Patient Care Services: Comprehensive pediatric healthcare services including inpatient care, outpatient specialty care, emergency services, diagnostic testing, and surgical procedures. Revenue generated through insurance reimbursements, government programs (Medicaid/CHIP), and patient payments.
2. Research Grants and Philanthropy: Funding from government agencies (NIH, NCI, ARPA-H), foundations (Gates Foundation, Gilbert Family Foundation, Wyss Foundation, Pew Charitable Trusts), and individual donors supporting clinical research, innovation programs, and facility development.
3. Diagnostic Testing Services: Specialized pediatric diagnostic testing through CHOP-Labcorp partnership, including advanced testing in oncology, metabolic disease, autoimmune conditions, genetics, and rare diseases.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels7 records

Core offering

Children's Hospital of Philadelphia operates as a comprehensive pediatric healthcare system delivering inpatient and outpatient clinical care, specialty medical services, surgical interventions, and emergency care to children. The institution also conducts translational and clinical research with a focus on gene therapy, rare diseases, pediatric cancer, and advanced diagnostics, and develops novel therapeutic platforms that have led to FDA-approved treatments.

Product overview

Children's Hospital of Philadelphia (CHOP) operates as a comprehensive pediatric healthcare system offering a wide range of medical services across multiple specialty centers and programs. The organization provides both clinical care and conducts extensive research, particularly in gene therapy, cancer treatment, cardiac care, and genetic diagnostics. CHOP's service portfolio includes major centers such as the Cancer Center, Cardiac Center, and specialized programs like the Gene Therapy for Inherited Metabolic Disorders Program and the Roberts Individualized Medical Genetics Center. The institution has pioneered innovative technologies including the VLP-Open HLA nanoparticle platform for cancer immunotherapy and the RareDAI AI tool for genetic test selection, as well as nanopore sequencing for ultra-rapid cancer diagnosis. CHOP also operates the Lurie Autism Institute and provides fetal diagnosis and treatment services.

Differentiator

Problem solved

Functional benefit

Brands

• PolicyLab: Research center focused on evidence-based solutions to improve child and family well-being through policy and systems work.
• Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment
• Spark Therapeutics
• Lurie Autism Institute
• Beverly L. Davidson, PhD

Products and services

• Cancer Center
• Cardiac Center
• Gene Therapy for Inherited Metabolic Disorders Program Program developing and delivering gene therapies for rare genetic metabolic disorders, including the world's first personalized CRISPR-based therapy for urea cycle disorders.
• Roberts Individualized Medical Genetics Center Center providing individualized medical genetics services for diagnosis and treatment of genetic conditions in children.
• Fetal Diagnosis and Treatment Center Center for fetal diagnosis and treatment offering prenatal care and fetal surgery for complex conditions diagnosed before birth, having performed over 2,500 fetal surgeries since 1995.
• Lurie Autism Institute Research institute focused on autism spectrum disorder research, collaboration, clinical care, and advocacy across the lifespan, launched with a $50 million gift.
• Behavioral Health and Crisis Center 24/7 specialized mental health care center in West Philadelphia serving pediatric patients ages 5-17 in its second year of operation.
• Undiagnosed Disease Program Program providing personalized care for families struggling to pinpoint the cause of their child's unexplained symptoms.
• Primary Care Services Pediatric primary care offices offering well visits, vaccinations, sick visits, and routine checkups from birth through young adulthood across 30+ locations.
• CHOP-Soar Autism Center Network Outpatient autism therapy services including speech, occupational, and behavioral therapy for children through age 6, using the Early Start Denver Model approach.

Quantifiable outcome

• World's first personalized CRISPR gene therapy patient achieved one-year milestone walking and talking
• +4 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Partnerships

Nine partnerships are on record, tiered core, minor and flagship.

• Department of Health - Abu DhabicoreStrategic or Co-development Partner · 24 June 2026MoU signed at BIO International Convention establishing strategic collaboration to advance gene editing capabilities for rare diseases. CHOP's gene therapy experts will provide specialized training to Abu Dhabi clinician-scientists in base-editing therapies targeting liver metabolic disorders, genetic clotting disorders, urea cycle disorders, and CNS conditions.
• Carnegie Mellon University (and 9-institution consortium)coreStrategic or Co-development Partner · 24 June 2026Multi-institutional team awarded up to $39.3 million from ARPA-H to develop OMEGA, a wearable AI-powered fetal monitoring system. CHOP participates in the nine-member consortium including UPMC Magee-Womens Hospital, University of Pittsburgh, and international partners, aiming to reduce unnecessary C-sections and improve neonatal outcomes.
• UAE EmbassyminorGTM or Marketing Partner · 18 June 2026Partnership to open a new year-round soccer field at Conestoga Park in West Philadelphia, serving as home of the West Philadelphia Soccer Academy. Part of UAE Embassy's program to build soccer fields in underserved US communities, coinciding with Philadelphia hosting 2026 FIFA World Cup.
• Latus BiocoreTechnology or Integration · 4 May 2026Philadelphia-based biotech company co-founded based on proprietary capsid technology licensed from CHOP, developing AAV gene therapy pipeline targeting Huntington's disease and CLN2 disease. Latus raised $97 million Series A including technology licensed from CHOP.
• LabcorpflagshipStrategic or Co-development Partner · 13 April 2026Strategic collaboration to accelerate discovery, development, and nationwide availability of specialized pediatric diagnostics. Combines CHOP's pediatric research expertise with Labcorp's national diagnostic infrastructure and commercialization capabilities through a joint innovation pipeline focused on oncology, metabolic disease, and autoimmune conditions.
• ChristianaCareflagshipStrategic or Co-development Partner · 1 April 2026Strategic affiliation launching April 1, 2026, bringing CHOP pediatric specialists to Delaware through the Center for Women's & Children's Health at ChristianaCare Newark campus. Features 24/7 Pediatric Care Center and Level III NICU, with initial focus on newborn care, hospitalist medicine, and pediatric emergency medicine, expanding to additional specialties over time.
• Soar Autism CenterflagshipStrategic or Co-development Partner · 22 January 2026Partnership to establish CHOP-Soar Autism Center network across Greater Philadelphia, with first center in Newtown (10,000 sq ft) serving children through age 6. Provides integrated speech, occupational, and behavioral therapy under one roof using Early Start Denver Model, with four more centers planned to create approximately 300 jobs.
• Hyundai Motor AmericaminorGTM or Marketing Partner · 11 October 2025Partnership for child safety seat check events at CHOP's King of Prussia Campus. Since 2022, Hyundai's support enabled distribution of over 1,600 new car seats and completion of over 2,000 safety inspections.
• Spark Therapeutics (CHOP spinout)coreTechnology or IntegrationCHOP spinout that manufactured and commercialized Luxturna, the first FDA-approved gene therapy for inherited blindness. The therapy, developed by CHOP and Penn Medicine researchers, received FDA approval in 2017.

Scale indicators8 records

Recent moves9 records

Expansion highlights9 records

Direct peers

• Seattle Children's Hospital: University of Washington-affiliated pediatric academic medical center and research institute. Comparable to CHOP in gene therapy research (notably in immunotherapy and rare disease), cancer treatment, and bone marrow transplant.
• Boston Children's Hospital: Harvard-affiliated pediatric academic medical center and the only other consistently top-ranked U.S. children's hospital. Direct competitor for complex pediatric referrals, gene therapy research, and specialty talent, with comparable gene therapy and rare disease programs.
• Cincinnati Children's Hospital Medical Center: Top-ranked pediatric research hospital and major NIH-funded research center. Competes directly with CHOP for pediatric research grants, gene therapy clinical trials, and U.S. News Honor Roll positioning.
• Texas Children's Hospital: Largest pediatric hospital in the U.S. and a Baylor College of Medicine affiliate. Competes with CHOP in complex pediatric care, research output, and specialty program scale, with overlapping cancer and cardiac centers.
• Children's National Hospital: Washington DC-based pediatric academic medical center and top-ranked children's hospital. Competes with CHOP for Mid-Atlantic specialty referrals and federal research funding, with strong genetics and fetal medicine programs.
• Nationwide Children's Hospital: Columbus, Ohio-based pediatric health system with extensive research institute and gene therapy programs. Direct competitor for complex pediatric cases and U.S. News Honor Roll positioning.
• Children's Hospital Los Angeles: USC-affiliated pediatric academic medical center consistently on the U.S. News Honor Roll. Direct peer across pediatric oncology, cardiac surgery, and translational research programs.
• Lucile Packard Children's Hospital Stanford: Stanford-affiliated pediatric academic medical center on the U.S. News Honor Roll. Competes with CHOP in pediatric cardiac surgery, neonatology, and translational genomics research.
• Children's Healthcare of Atlanta: Large pediatric health system affiliated with Emory University, operating three hospitals. Comparable to CHOP in pediatric cancer, cardiac care, and research output, serving as a Southeast U.S. counterpart.

Regional players

• UPMC Children's Hospital of Pittsburgh: UPMC-affiliated pediatric hospital in Pennsylvania that shares state-level pediatric specialty referrals with CHOP and was a co-recipient of the $30M Jared Isaacman donation. Regional peer in the Pennsylvania pediatric market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ChildrensPhila
• Facebookfacebook.com/ChildrensHospitalofPhiladelphia

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries5 records

Funding overview

Funding rounds14 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Children's Hospital of Philadelphia